Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  European Journal of Pharmacology

• Publication date

  2015-08-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ejphar.2015.05.020PMID 25981302
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)

  2015cited by this paper
• Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease

  2015cited by this paper
• Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis.

  2014cited by this paper
• Translational Study Searching for Synergy between Glycopyrronium and Indacaterol

  2014cited by this paper
• Treatment of Chronic Obstructive Pulmonary Disease by Dual Bronchodilation with Coformulation of Indacaterol/Glycopyrronium

  2014cited by this paper
• Efficacy and safety of a fixed-dose combination of indacaterol and Glycopyrronium for the treatment of COPD: a systematic review.

  2014cited by this paper
• Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi.

  2014cited by this paper
• Bronchodilators: current and future.

  2014cited by this paper
• New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol

  2013cited by this paper
• Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease

  2013cited by this paper
• Effect of the Mixed Phosphodiesterase 3/4 Inhibitor RPL554 on Human Isolated Bronchial Smooth Muscle Tone

  2013cited by this paper
• Muscarinic receptors on airway mesenchymal cells: novel findings for an ancient target.

  2013cited by this paper
• Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study.

  2013cited by this paper
• Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study

  2013cited by this paper
• The influence of propofol, remifentanil and lidocaine on the tone of human bronchial smooth muscle.

  2013cited by this paper
• Phenotypic characteristics of patients with arterial hypertension and chronic obstructive pulmonary disease

  2012cited by this paper
• Revisiting the Isobole and Related Quantitative Methods for Assessing Drug Synergism

  2012cited by this paper
• Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes.

  2012cited by this paper
• Tiotropium in asthma poorly controlled with standard combination therapy.

  2012cited by this paper
• Emerging drugs for chronic obstructive pulmonary disease

  2012cited by this paper
• Dose-finding study for tiotropium and olodaterol when administered in combination via the Respimat® inhaler in patients with COPD

  2012cited by this paper
• High glucose enhances responsiveness of human airways smooth muscle via the Rho/ROCK pathway.

  2012cited by this paper
• The Influence of Receptor Kinetics on the Onset and Duration of Action and the Therapeutic Index of NVA237 and Tiotropium

  2012cited by this paper
• Pharmacological characterization of adenosine receptors on isolated human bronchi.

  2011cited by this paper
• Quantum mechanics can reduce the complexity of classical models

  2011cited by this paper
• Epithelium integrity is crucial for the relaxant activity of brain natriuretic peptide in human isolated bronchi

  2011cited by this paper
• Evaluation of the effects of the R- and S-enantiomers of salbutamol on equine isolated bronchi.

  2011cited by this paper
• Protein prenylation contributes to the effects of LPS on EFS-induced responses in human isolated bronchi.

  2011cited by this paper
• P139 Atelectasis following bronchoscopic lung volume reduction (BLVR) is associated with improved survival in COPD

  2010cited by this paper
• The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD.

  2010cited by this paper
• Relaxant effect of brain natriuretic peptide in nonsensitized and passively sensitized isolated human bronchi.

  2009cited by this paper
• Characterization of Aclidinium Bromide, a Novel Inhaled Muscarinic Antagonist, with Long Duration of Action and a Favorable Pharmacological Profile

  2009cited by this paper
• Effects of neuraminidase on equine isolated bronchi.

  2008cited by this paper
• Novel long‐acting bronchodilators for COPD and asthma

  2008cited by this paper
• Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.

  2007cited by this paper
• A mathematical approach to study combined effects of toxicants in vitro: evaluation of the Bliss independence criterion and the Loewe additivity model.

  2007cited by this paper
• Combination Inhaled Bronchodilator Therapy in the Management of Chronic Obstructive Pulmonary Disease

  2007cited by this paper
• Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies

  2006cited by this paper
• Immune sensitization of equine bronchus: glutathione, IL-1β expression and tissue responsiveness

  2005cited by this paper
• Signaling and regulation of G protein-coupled receptors in airway smooth muscle

  2003cited by this paper
• Respiratory Research BioMed Central Review

  2002cited by this paper

• Triple drug co-delivery within nanosystems for synergistic anti-infective, anti-inflammatory, antinociceptive and neuroregenerative therapeutic effects: a focus on pharmacological and nanotechnological aspects.

  2026cites this paper
• Airway mucus and 129Xe MRI ventilation after single inhaler triple therapy in asthma

  2025cites this paper
• Mining of Adverse Event Signals Associated with Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy: A Post-Marketing Analysis Based on FAERS

  2025cites this paper
• Drug-Drug Interactions and Synergy: From Pharmacological Models to Clinical Application

  2024cites this paper
• The Saudi Thoracic Society Evidence-based guidelines for the diagnosis and management of chronic obstructive pulmonary disease

  2024cites this paper
• Pulmonary inhalation for disease treatment: Basic research and clinical translations

  2024cites this paper
• Unraveling the Impact of Salbutamol Polytherapy: Clinically Relevant Drug Interactions

  2023influential citation
• When is LABA/LAMA Better than LAMA in GOLD Group B or D Patients for Reducing Acute Exacerbations of COPD?

  2023cites this paper
• The Role of Long-Acting Antimuscarinic Agents in the Treatment of Asthma

  2023cites this paper
• Is it preferable to administer a bronchodilator once- or twice-daily when treating COPD?

  2023cites this paper
• Real-world effects of once-daily inhaled steroid (fluticasone furoate) combined with long-acting beta-2 agonist (vilanterol) and long-acting muscarinic antagonist (umeclidinium) on lung function tests of asthma patients in Japan

  2023cites this paper
• Burden and unmet needs in asthma care in the Asia‐Pacific region

  2022cites this paper
• Optimization of Long-Acting Bronchodilator Dose Ratios Using Isolated Guinea Pig Tracheal Rings for Synergistic Combination Therapy in Asthma and COPD

  2022influential citation
• Dual bronchodilation for the treatment of COPD: From bench to bedside

  2022cites this paper
• Understanding COPD: Current Treatments and Emerging Breakthroughs

  2022cites this paper
• Beyond Dual Bronchodilation – Triple Therapy, When and Why

  2022cites this paper
• Tiotropium Bromide Attenuates Mucus Hypersecretion in Patients with Stable Chronic Obstructive Pulmonary Disease

  2021cites this paper
• ОПЫТ ПРИМЕНЕНИЯ ДВОЙНОЙ БРОНХОДИЛАТАЦИОННОЙ ТЕРАПИИ У ПАЦИЕНТОВ С ХОБЛ

  2021cites this paper
• Role of Airway Smooth Muscle in Inflammation Related to Asthma and COPD.

  2021cites this paper
• Comparative studies of dual bronchodilation in COPD.

  2021cites this paper
• Inhaled long-acting muscarinic antagonists in asthma - A narrative review.

  2021cites this paper
• Long‐acting muscarinic antagonists and small airways in asthma: Which link?

  2021cites this paper
• Synergy across the drugs approved for the treatment of asthma.

  2021cites this paper
• Pharmacokinetic/pharmacodynamic approaches to drug delivery design for inhalation drugs

  2021cites this paper
• Determination of an appropriate dose ratio of a synergistic combination of long-acting bronchodilators for the maintenance treatment of asthma and COPD

  2021influential citation
• Pharmacological interactions: Synergism, or not synergism, that is the question

  2021cites this paper
• Drug interaction and chronic obstructive respiratory disorders

  2020cites this paper
• Effectiveness and tolerability of formoterol plus glycopyrronium combination in patients with chronic obstructive pulmonary disease: FINE registry

  2020cites this paper
• Beclomethasone dipropionate and sodium cromoglycate protect against airway hyperresponsiveness in a human ex vivo model of cow's milk aspiration

  2020cites this paper
• Synergy in Whole Plant Medicine:Crataegusspp.: An Example

  2020cites this paper
• First-Line Treatment with Tiotropium/Olodaterol Improves Physical Activity in Patients with Treatment-Naïve Chronic Obstructive Pulmonary Disease

  2020cites this paper
• COPD_A_268905 2115..2126

  2020cites this paper
• COPD_A_240033 1269..1285

  2020cites this paper
• Day and Night Control of COPD and Role of Pharmacotherapy: A Review

  2020cites this paper
• Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: Synergy of triple combination therapy on human airway smooth muscle ex vivo

  2020cites this paper
• The role of triple therapy in the management of COPD

  2020cites this paper
• Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: Synergy of triple combination therapy on human airway smooth muscle ex vivo

  2020cites this paper
• The reality of LAMAs for adult asthmatic patients

  2020cites this paper
• Pharmacology and Therapeutics of Bronchodilators Revisited

  2019cites this paper
• COPD_A_198288 799..808

  2019cites this paper
• A potential role of triple therapy for asthma patients

  2019cites this paper
• Pharmacological Profile of AZD8871 (LAS191351), a Novel Inhaled Dual M3 Receptor Antagonist/β2-Adrenoceptor Agonist Molecule with Long-Lasting Effects and Favorable Safety Profile

  2019cites this paper
• Second M3 muscarinic receptor binding site contributes to bronchoprotection by tiotropium

  2019cites this paper
• Relationship of inhaled long-acting bronchodilators with cardiovascular outcomes among patients with stable COPD: a meta-analysis and systematic review of 43 randomized trials

  2019cites this paper
• Triple Therapy in COPD

  2019cites this paper
• Optimizing the Development Strategy of Combination Therapy in Respiratory Medicine: From Isolated Airways to Patients

  2019cites this paper
• Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β2-agonist fixed-dose combinations in COPD

  2019cites this paper
• Pharmacological treatment and current controversies in COPD

  2019cites this paper
• Management of severe COPD exacerbations: focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide

  2018cites this paper
• Dual LABA/LAMA bronchodilators in chronic obstructive pulmonary disease: why, when, and how

  2018cites this paper
• Combining long‐acting bronchodilators with different mechanisms of action: A pharmacological approach to optimize bronchodilation of equine airways

  2018cites this paper
• Pharmacological mechanisms leading to synergy in fixed‐dose dual bronchodilator therapy

  2018cites this paper
• Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways

  2018influential citation
• The safety of dual bronchodilation on cardiovascular serious adverse events in COPD

  2018cites this paper
• Indacaterol/Glycopyrronium in Clinical Practice: The Italian Experience

  2018cites this paper
• Editorial overview: Respiratory: Pulmonary pharmacology - It is time for a breath of fresh air.

  2018cites this paper
• Patient considerations in the treatment of COPD: focus on the new combination inhaler fluticasone furoate/umeclidinium/vilanterol

  2018cites this paper
• Involvement of Allosteric Effect and KCa Channels in Crosstalk between β2-Adrenergic and Muscarinic M2 Receptors in Airway Smooth Muscle

  2018influential citation
• Classical and Emerging Therapies against Chronic Obstructive Pulmonary Disease

  2018cites this paper
• The mode of action of anticholinergics in asthma

  2018cites this paper
• New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology

  2018influential citation
• LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review

  2018cites this paper
• Double or Triple Therapy in Chronic Obstructive Pulmonary Disease

  2018cites this paper
• Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease.

  2018cites this paper
• An Update on the Global Initiative for Chronic Obstructive Lung Disease 2017 Guidelines With a Focus on Classification and Management of Stable COPD

  2018cites this paper
• LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review

  2018cites this paper
• Inhaled nebulised unfractionated heparin improves lung function in moderate to very severe COPD: A pilot study.

  2018cites this paper
• Patient considerations in the treatment of COPD: focus on the new combination inhaler fluticasone furoate/umeclidinium/vilanterol

  2018cites this paper
• Management of severe COPD exacerbations: focus on beclomethasone dipropionate/ formoterol/glycopyrronium bromide

  2018cites this paper
• The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis

  2017cites this paper
• Gender-related Responsiveness to the Pharmacological Treatment of COPD: A First Step Towards the Personalized Medicine

  2017cites this paper
• A review of current and developing fixed-dose LABA/LAMA combinations for treating COPD

  2017cites this paper
• -AGONISTS IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

  2017influential citation
• Inhaled nebulised unfractionated heparin improves lung function in moderate to very severe COPD: A pilot study

  2017cites this paper
• Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi

  2017cites this paper
• Safety of inhaled long-acting anti-muscarinic agents in COPD

  2017cites this paper
• Bivalent ligand that activates mu opioid receptor and antagonizes mGluR5 receptor reduces neuropathic pain in mice

  2017cites this paper
• Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD—a randomised controlled study

  2017cites this paper
• Umeclidinium for the treatment of uncontrolled asthma

  2017cites this paper
• Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD

  2017cites this paper
• Impact of LABA/LAMA combination on exercise endurance and lung hyperinflation in COPD: A pair-wise and network meta-analysis.

  2017cites this paper
• Role of dual bronchodilators in COPD: A review of the current evidence for indacaterol/glycopyrronium.

  2017cites this paper
• LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment

  2017cites this paper
• Pharmacological characterization of the interaction between tiotropium and olodaterol administered at 5:5 concentration-ratio in equine bronchi

  2017influential citation
• Indacaterol/Glycopyrronium Combination for COPD

  2017cites this paper
• The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis

  2017cites this paper
• Efficacy of tiotropium–olodaterol fixed-dose combination in COPD

  2016cites this paper
• Long-term safety of aclidinium bromide/formoterol fumarate fixed-dose combination: Results of a randomized 1-year trial in patients with COPD.

  2016cites this paper
• COPD pharmacological treatment : efficacy and tolerability profiles in the elderly patient . Focus on aclidinium bromide

  2016cites this paper
• Olodaterol + tiotropium bromide for the treatment of COPD

  2016cites this paper
• Treatment options for moderate-to-very severe chronic obstructive pulmonary disease

  2016cites this paper
• Dual bronchodilation and exacerbations of COPD.

  2016cites this paper
• Onset of action of budesonide/formoterol Spiromax(®) compared with budesonide/formoterol Turbuhaler(®) in patients with COPD.

  2016cites this paper
• Brain natriuretic peptide: Much more than a biomarker.

  2016cites this paper
• Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells

  2016influential citation
• Formoterol fumarate + glycopyrrolate for the treatment of chronic obstructive pulmonary disease

  2016influential citation
• Oxidation pathway and exacerbations in COPD: the role of NAC

  2016cites this paper
• Efficacy of tiotropium–olodaterol fixed-dose combination in COPD

  2016cites this paper
• Glucagon-Like Peptide 1 Receptor: A Novel Pharmacological Target for Treating Human Bronchial Hyperresponsiveness.

  2016cites this paper
• Specific role of combination aclidinium: formoterol in the treatment of chronic obstructive pulmonary disease

  2016cites this paper